Open AccessCYCLOSPORINE-ASSOCIATED HYPERTENSION IN CARDIOPULMONARY TRANSPLANTATION
Author(s) -
Alan Kirk,
Omar Irfan,
D. N. Bateman,
J.H. Dark
Publication year - 1989
Publication title -
transplantation
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-198909000-00015
Subject(s) - nifedipine , medicine , renal function , creatinine , pulmonary hypertension , transplantation , lung transplantation , prazosin , heart transplantation , urology , cardiology , anesthesia , antagonist , receptor , calcium
In a retrospective review of fifty heart, lung, and heart-lung recipients receiving cyclosporine, forty-six (92%) were hypertensive. This hypertension was managed with either prazosin (n = 29) or nifedipine (n = 17). Renal function was assessed by creatinine clearance estimation and found to be significantly better in those patients receiving nifedipine. (creatinine clearance = 60 ml/min [SEM 5.7] vs. 49 ml/min [SEM 2.7]; P less than 0.05). This observation suggests that nifedipine should be the drug of choice for the treatment of cyclosporine-associated hypertension in cardiac and pulmonary transplant recipients.